184 related articles for article (PubMed ID: 20069329)
1. Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis.
Tesija-Kuna A; Grazio S; Miler M; Vukasovic I; Peric P; Vrkic N
Clin Rheumatol; 2010 May; 29(5):487-93. PubMed ID: 20069329
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.
Nicaise Roland P; Grootenboer Mignot S; Bruns A; Hurtado M; Palazzo E; Hayem G; Dieudé P; Meyer O; Chollet Martin S
Arthritis Res Ther; 2008; 10(6):R142. PubMed ID: 19077182
[TBL] [Abstract][Full Text] [Related]
5. Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris.
Dalmády S; Kiss M; Képíró L; Kovács L; Sonkodi G; Kemény L; Gyulai R
Clin Dev Immunol; 2013; 2013():474028. PubMed ID: 23573111
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis.
Kuna AT; Lamot L; Miler M; Harjacek M; Simundic AM; Vrkic N
Clin Chem Lab Med; 2009; 47(12):1525-30. PubMed ID: 19842993
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
[TBL] [Abstract][Full Text] [Related]
8. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis.
Inanc N; Dalkilic E; Kamali S; Kasapoglu-Günal E; Elbir Y; Direskeneli H; Inanc M
Clin Rheumatol; 2007 Jan; 26(1):17-23. PubMed ID: 16538391
[TBL] [Abstract][Full Text] [Related]
9. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
Zhu T; Feng L
Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
Maraina CH; Nurdayana AK; Rusni D; Azwany Y
Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
[TBL] [Abstract][Full Text] [Related]
11. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy.
Zehairy M; Soliman E; Daghaidy A
Rheumatol Int; 2012 Nov; 32(11):3495-501. PubMed ID: 22068352
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
Keskin G; Inal A; Keskin D; Pekel A; Baysal O; Dizer U; Sengül A
Protein Pept Lett; 2008; 15(3):314-7. PubMed ID: 18336364
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
[TBL] [Abstract][Full Text] [Related]
16. Unique correlation between mutated citrullinated vimentine IgG autoantibodies and markers of systemic inflammation in rheumatoid arthritis patients.
Zahran WE; Mahmoud MI; Shalaby KA; Abbas MH
Indian J Clin Biochem; 2013 Jul; 28(3):272-6. PubMed ID: 24426223
[TBL] [Abstract][Full Text] [Related]
17. [Antibodies to mutated citrullinated vimentin and some associated autoantibodies in juvenile idiopathic arthritis].
Zhang L; Ru J; Jie X; Che G; Jin X; Li X
Zhonghua Er Ke Za Zhi; 2015 Dec; 53(12):948-51. PubMed ID: 26887552
[TBL] [Abstract][Full Text] [Related]
18. Anti-mutated citrullinated vimentin antibody and rheumatoid factor (prevalence and association) in rheumatoid arthritis patients; Saudi and non-Saudi.
Safi MA; Attar SM; Fathaldin OA; Safi OM
Clin Lab; 2015; 61(3-4):259-67. PubMed ID: 25974991
[TBL] [Abstract][Full Text] [Related]
19. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
[TBL] [Abstract][Full Text] [Related]
20. Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis.
Koivula MK; Heliövaara M; Rissanen H; Palosuo T; Knekt P; Immonen H; Risteli J
Ann Rheum Dis; 2012 Oct; 71(10):1666-70. PubMed ID: 22419777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
